ABEONA THERAPEUTICS INC. short interest in 2019
In 2019, ABEONA THERAPEUTICS INC.'s disclosed short interest ran from 0.00% of shares outstanding on 15 Jan 2019 to 7.97% on 31 Dec 2019, a change of +7.97 percentage points. The year's high was 9.42% on 15 Nov 2019 and its low 0.00% on 15 Jan 2019, averaging 1.69% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 41.67 days on 15 Apr 2019. Full history: ABEONA THERAPEUTICS INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2019 in figures
- Start of year
- 0.00% (15 Jan 2019)
- End of year
- 7.97% (31 Dec 2019)
- Change
- +7.97 pp
- High
- 9.42% (15 Nov 2019)
- Low
- 0.00% (15 Jan 2019)
- Average
- 1.69%
- Highest days to cover
- 41.67 (15 Apr 2019)
- SEC filings marked
- 8
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 0.00% | 1.00 | |
| 31 Jan 2019 | 0.00% | 7.26 | |
| 15 Feb 2019 | 0.00% | 5.55 | |
| 15 Mar 2019 | 0.00% | 22.73 | |
| 29 Mar 2019 | 0.00% | 1.00 | 10-K filed, results (8-K) |
| 15 Apr 2019 | 0.00% | 41.67 | |
| 30 Apr 2019 | 0.00% | 1.35 | |
| 15 May 2019 | 0.00% | 1.45 | 10-Q filed, results (8-K) |
| 31 May 2019 | 0.00% | 1.00 | |
| 28 Jun 2019 | 0.00% | 1.00 | |
| 15 Jul 2019 | 0.00% | 1.00 | |
| 31 Jul 2019 | 0.00% | 1.00 | |
| 15 Aug 2019 | 0.00% | 1.59 | 10-Q filed, results (8-K) |
| 30 Aug 2019 | 0.01% | 3.09 | |
| 13 Sep 2019 | 0.01% | 1.00 | |
| 30 Sep 2019 | 0.01% | 3.83 | |
| 15 Nov 2019 | 9.42% | 20.55 | 10-Q filed, results (8-K) |
| 29 Nov 2019 | 8.45% | 8.12 | |
| 13 Dec 2019 | 7.93% | 2.46 | |
| 31 Dec 2019 | 7.97% | 1.51 |
See also: ABEONA THERAPEUTICS INC.'s full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.